News
IMCR
28.88
-3.54%
-1.06
Weekly Report: what happened at IMCR last week (1109-1113)?
Weekly Report · 1d ago
Immunocore Holdings Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 3d ago
Immunocore Holdings Price Target Cut to $42.00/Share From $43.00 by Morgan Stanley
Dow Jones · 3d ago
Morgan Stanley Maintains Equal-Weight on Immunocore Holdings, Lowers Price Target to $42
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR) and Kardigan, Inc. (KARD)
TipRanks · 4d ago
Immunocore price target lowered to $80 from $100 at H.C. Wainwright
TipRanks · 6d ago
Immunocore Holdings Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/10 11:58
Immunocore Holdings Price Target Cut to $80.00/Share From $100.00 by HC Wainwright & Co.
Dow Jones · 11/10 11:58
HC Wainwright & Co. Maintains Buy on Immunocore Holdings, Lowers Price Target to $80
Benzinga · 11/10 11:48
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunocore Holdings (IMCR), Pharvaris (PHVS) and Moderna (MRNA)
TipRanks · 11/09 13:40
Weekly Report: what happened at IMCR last week (1102-1106)?
Weekly Report · 11/09 09:18
Is Immunocore Holdings (IMCR) Undervalued On Third Quarter Earnings?
Simply Wall St · 11/09 06:25
Immunocore Stock Is Up 9.1% Has The Bull Case Changed?
Simply Wall St · 11/08 05:32
Immunocore presents Phase 1/2 trial cohort data of brenetafusp plus KIMMTRAK
TipRanks · 11/06 17:10
Immunocore Holdings Announces Data Form Its Phase 1/2 Study Of Brenetafusp Shows 29% Overall Response Rate, 71% Disease Control Rate
Benzinga · 11/06 17:01
Immunocore reports Q3 EPS (28c), consensus (13c)
TipRanks · 11/06 14:17
Immunocore Hldgs Q3 EPS $(0.28) Misses $(0.10) Estimate, Sales $102.222M Miss $113.438M Estimate
Benzinga · 11/06 14:04
H.C. Wainwright Sticks to Their Buy Rating for Immunocore Holdings (IMCR)
TipRanks · 11/04 17:45
Weekly Report: what happened at IMCR last week (1026-1030)?
Weekly Report · 11/02 09:18
Immunocore’s Tebentafusp Data Refresh: What the Updated Uveal Melanoma Trial Means for IMCR Investors
TipRanks · 10/29 16:30
More
Webull provides a variety of real-time IMCR stock news. You can receive the latest news about Immunocore Holdings Plc through multiple platforms. This information may help you make smarter investment decisions.
About IMCR
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.